A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)
NCT ID: NCT01195636
Last Updated: 2013-11-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
70 participants
INTERVENTIONAL
2010-08-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
XPF-002
XPF-002
Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
Placebo
Placebo
Twice daily application of Placebo ointment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
XPF-002
Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
Placebo
Twice daily application of Placebo ointment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males or females of non-childbearing potential (ie, 12 months or more of spontaneous amenorrhea, bilateral oophorectomy at least 6 months prior to randomization, hysterectomy with bilateral oophorectomy at least 6 months prior to randomization, or for females over 50 years of age, hysterectomy without bilateral oophorectomy at least 6 months prior to randomization);
* Male subjects with sexual partners of childbearing potential must agree to use contraception (abstinence, birth control pills, rings or patches, diaphragm and spermicide, intrauterine device, condom and vaginal spermicide, surgical sterilization, vasectomy, progestin implant or injection);
* Persistent pain for more than 6 months from the appearance of herpes zoster rash that is not located on the face, above the scalp hairline, or in proximity to mucous membranes;
* Diagnosis of PHN;
* Persistent neuropathic pain that involves at least 1 dermatome and covering no more than 400 cm2;
* Mean daily pain intensity score in the target area of greater than or equal to 4 on an 11-point Likert NRS for a minimum of 4 days during the single-blind, placebo run-in period;
* Subject agrees to take only the protocol-defined rescue medication as prescribed;
* Intact skin over the painful area to be treated; and
* Able and willing to provide informed consent and comply with study procedures.
Exclusion Criteria
* Creatinine clearance less than 30 mL/min;
* Subject with known history of human immunodeficiency virus, hepatitis C, or hepatitis B;
* Malignancy other than basal cell carcinoma and carcinoma in situ within the past 2 years;
* Subject with history of serious mental illness or psychiatric illness such as dementia, depression, or schizophrenia, that will limit his/her ability to comply with study procedures;
* Subject who is unable to apply, or have a care giver apply, study ointment to the area of most painful skin segments, BID, once within 2 hours of waking and once in the evening after dinner;
* Subject with known sensitivity to topical products;
* Subject with active herpes zoster lesions or dermatitis;
* Other severe or chronic pain that may impair the self-assessment of the pain due to PHN;
* Treatment with local anesthetic in the last 2 weeks or nerve blocks within the last 30 days;
* Subject who is taking any opioid medications to treat his/her PHN pain and is unable to washout of these medications for the duration of the study;
* Subject who is taking any prohibited medication and is unable to washout of these treatments for the duration of the study;
* Subject who is taking more than 2 permitted concomitant medications for the treatment of PHN and is unable to washout of all but 2 of these treatments for the duration of the study;
* Subject who is taking any local prescription or non-prescription therapy (lidocaine patch, transcutaneous electrical nerve stimulation, etc.) and is unable to washout of these treatments for the duration of the study;
* Subject who has used Qutenza® patches in the 90 days prior to screening or has used other capsaicin preparations on a daily basis in the 90 days prior to screening;
* Subject who has participated in more than 1 other topical study for pain and more than 3 other PHN clinical studies;
* Pregnant or lactating females;
* Subject who has an active history of alcohol or drug abuse;
* Subject who has participated in any other investigational study within 60 days prior to screening;
* Subject who is employed by the Sponsor, study staff, and their families; or
* Subject who has any condition that would make him/her, in the opinion of the investigator or Sponsor, unsuitable for the study.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xenon Pharmaceuticals Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jonesboro, Arkansas, United States
Lomita, California, United States
Westlake Village, California, United States
Bradenton, Florida, United States
Naples, Florida, United States
New Port Richey, Florida, United States
Ocala, Florida, United States
Sunrise, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
Marietta, Georgia, United States
Lexington, Kentucky, United States
Bay City, Michigan, United States
St Louis, Missouri, United States
Las Vegas, Nevada, United States
Albuquerque, New Mexico, United States
Hartsdale, New York, United States
Oklahoma City, Oklahoma, United States
Philadelphia, Pennsylvania, United States
West Reading, Pennsylvania, United States
Austin, Texas, United States
Houston, Texas, United States
Sugar Land, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XPF-002-201
Identifier Type: -
Identifier Source: org_study_id